Company Overview - Bausch + Lomb is a global leader in eye health, operating across three key segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical [7] - The company leverages a diversified product portfolio and extensive distribution network to serve healthcare professionals and consumers [7] - Bausch + Lomb generates revenue through the sale of branded and generic eye health products to healthcare providers, clinics, and direct-to-consumer channels globally [9] Financial Metrics - As of March 23, 2026, the company's stock price was $15.84, with a market capitalization of $5.61 billion [4] - The trailing twelve months (TTM) revenue was $5.10 billion, while the net income for the same period was a loss of $360 million [4] Recent Insider Activity - Alfonso Eduardo, a director at Bausch + Lomb, purchased 4,300 shares for approximately $77,000, which triggered an equal grant of 4,300 restricted share units under the company's matching share program [2][3] - This transaction increased Eduardo's total holdings from roughly 5,255 to 13,855 shares, moving him closer to a mandatory director ownership threshold of $400,000 [3] Market Context - The shares were acquired at $17.90, a small discount to the March 2 closing price of $18.41, indicating a strategic purchase aligned with the director's ownership requirements [6] - The matching program allows directors to build their equity stake efficiently while ensuring alignment with retail investors [8]

Company Overview - National Vision is a leading U.S. optical retailer with a broad footprint across physical and digital channels, leveraging a multi-brand strategy to serve cost-sensitive customers [5] - The company generates revenue primarily through retail sales of optical products and services, supported by a network of over 1,200 stores and online channels [7] - National Vision reported a total revenue of $1.99 billion and a net income of $29.60 million for the trailing twelve months (TTM) [4] Recent Transaction - CEO Alexander Wilkes sold 35,000 shares of National Vision common stock for a total transaction value of $929,000, reducing his direct holdings by 68.05% to 16,431 shares [2][6] - The sale was executed under a Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than opportunistic [6][8] - The shares were sold at approximately $26.54 each, with the stock having increased by 118.4% over the prior year [6][9] Market Context - National Vision's stock reached a 52-week high of $30.02 in January, driven by strong financial results, including a 15% year-over-year revenue increase in the fiscal fourth quarter [9] - The company's price-to-earnings ratio is currently at 72, suggesting that the stock may be considered expensive, indicating a potential time to sell rather than buy [10]

Company Overview - The Cooper Companies, Inc. (COO) is based in California and specializes in developing, manufacturing, and marketing products for contact lens wearers, with a market capitalization of $13.9 billion [1] - COO operates in two segments: CooperVision, which offers various types of contact lenses, and CooperSurgical, which provides fertility products, medical devices, contraception, and cryostorage services for women [1] Market Performance - COO stock has decreased by 20.9% from its 52-week high of $89.83 reached on December 5, 2025, and has declined 12.3% over the past three months, underperforming the Dow Jones Industrials Average, which fell by 2.4% during the same period [3][6] - Over the past 52 weeks, COO has seen a decline of 12.5%, while the Dow Jones Industrials Average has gained 13.2% [6] Recent Earnings Report - On March 5, COO reported mixed Q1 2026 earnings, with revenue increasing nearly 6% year-over-year to $1 billion, aligning with market estimates [7] - The adjusted EPS for the quarter rose by 20% from the previous year to $1.10, surpassing Wall Street expectations [7] - Despite the positive earnings, investor confidence waned due to weak organic revenue growth and slower business performance in the Asia Pacific region, leading to a 4.6% drop in stock price in the following trading session [7] Competitive Positioning - Compared to its peer Align Technology, Inc. (ALGN), COO has underperformed, with ALGN stock growing by 2% over the past year [8] - Sentiment towards COO remains moderately optimistic, with a consensus rating of "Moderate Buy" among 18 analysts and a mean price target of $90.81, indicating a potential upside of 27.8% from current levels [8]

Core Insights - The Cooper Companies reported total revenue of $1.02 billion for the quarter ending January 2026, reflecting a 6.2% increase from the previous year [4] International Revenue Analysis - EMEA contributed 27.6% of total revenue, amounting to $282.3 million, surpassing analyst expectations of $269.49 million with a surprise of +4.76% [5] - Asia Pacific generated $123.8 million, representing 12.1% of total revenue, falling short of the consensus estimate of $136.81 million with a surprise of -9.51% [6] Revenue Forecasts - Analysts project total revenue of $1.06 billion for the current fiscal quarter, a 5.4% increase year-over-year, with EMEA and Asia Pacific expected to contribute $267.79 million (25.4%) and $142.16 million (13.5%) respectively [7] - For the full year, total revenue is anticipated to reach $4.32 billion, a 5.6% increase from the previous year, with EMEA and Asia Pacific expected to account for $1.13 billion (26.2%) and $577.79 million (13.4%) respectively [8] Market Context - The reliance on international markets presents both opportunities and challenges for The Cooper Companies, making the analysis of international revenue trends crucial for future forecasts [9] - Analysts are closely monitoring these trends in the context of increasing global interdependencies and geopolitical tensions, which can impact earnings predictions [10]

Core Viewpoint - Alcon (ALC) is expected to report quarterly earnings of $0.79 per share, a 9.7% increase year-over-year, with revenues projected at $2.71 billion, reflecting a 9.3% year-over-year growth [1]. Earnings Estimates - The consensus EPS estimate for the quarter has been revised upward by 1.5% over the past 30 days, indicating analysts' reappraisal of their initial projections [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Key Metrics Projections - Analysts project 'Net Sales- Total Surgical- Equipment/other' to be $277.54 million, a 21.2% increase from the prior-year quarter [5]. - 'Net Sales- Total Surgical- Implantables' is expected to reach $482.10 million, indicating a 5.7% year-over-year change [5]. - The estimate for 'Net Sales- Total Surgical' is $1.56 billion, reflecting a 9.3% increase year-over-year [5]. - 'Net Sales- Total Vision care' is projected at $1.15 billion, a 9.1% increase from the previous year [6]. - 'Net Sales- Total Surgical- Consumables' is expected to be $796.13 million, indicating a 7.9% year-over-year change [6]. - The consensus for 'Net Sales- Total Vision Care- Contact lenses' stands at $687.14 million, reflecting a 7.7% increase [6]. - 'Net Sales- Total Vision Care- Ocular health' is projected to reach $462.70 million, a change of 11.2% from the prior-year quarter [7]. - 'Net Sales and other revenues- Other revenues' is estimated at $26.18 million, suggesting a 4.7% year-over-year change [7]. Stock Performance - Over the past month, Alcon shares have returned +0.8%, while the Zacks S&P 500 composite has changed by -0.8% [7]. - Alcon holds a Zacks Rank 3 (Hold), indicating that its performance is expected to align with the overall market in the upcoming period [7].

Company Overview - The Cooper Companies (COO) is a global medical device company based in San Ramon, California, specializing in the development, manufacturing, and marketing of contact lenses and related products, with a market cap of $16.3 billion [1]. Stock Performance - COO shares have underperformed the broader market over the past year, declining 7%, while the S&P 500 Index has increased by nearly 11.9% [2]. - Year-to-date, COO stock has seen marginal losses, aligning with a slight fall in the S&P 500 Index [2]. - Compared to the SPDR S&P Health Care Equipment ETF (XHE), which has declined about 6.6% over the past year, COO's year-to-date performance shows a smaller decline than the ETF's 3.3% [3]. Financial Results - On December 4, 2025, COO reported Q4 results with revenue of $1.07 billion, exceeding analyst estimates of $1.06 billion [4]. - The adjusted EPS for the quarter was $1.15, beating analyst expectations by 3.2% [4]. - For the current fiscal year ending in October, analysts project a 9.5% growth in EPS to $4.51 on a diluted basis [4]. - COO has a strong earnings surprise history, having beaten or matched consensus estimates in each of the last four quarters [4]. Analyst Ratings - Among 18 analysts covering COO stock, the consensus rating is a "Moderate Buy," consisting of 10 "Strong Buy" ratings, one "Moderate Buy," six "Holds," and one "Strong Sell" [5]. - The sentiment has improved compared to a month ago, where nine analysts previously suggested a "Strong Sell" [6]. - Needham maintained a "Buy" rating on COO, lowering the price target to $99, indicating a potential upside of 20.8% from current levels [6]. - The mean price target is $90.12, representing a 10% premium to COO's current price, while the highest price target of $100 suggests an upside potential of 22% [6].

Company Overview - Cooper Companies was founded in 1958 and has been listed on the S&P 500 since 2016 [1] - The company operates under two main business units: CooperVision and CooperSurgical [1] - CooperVision is the leading contact lens company globally, ranked 1 in terms of wearers and 2 in revenue [1] - CooperSurgical specializes in fertility and women's health care, focusing on non-pharmaceutical medical devices [1] Employee and Market Reach - The company employs over 15,000 individuals worldwide [2] - More than 50 million people use Cooper's products, including contact lenses and women's health care products [2] - Approximately 42 million patients annually wear Cooper's contact lenses [2] - CooperVision accounts for about two-thirds of the company's consolidated revenues [2]

Company Overview - Warby Parker Inc. is a vertically integrated eyewear company focused on accessible, design-driven products and a seamless omnichannel experience, leveraging both physical retail and digital channels to reach a broad customer base [7] - The company offers prescription eyeglasses, sunglasses, contact lenses, and vision care accessories, generating revenue primarily from eyewear sales and related services [10] Recent Transaction Details - Co-Chief Executive Officer David Abraham Gilboa sold 94,906 shares for approximately $2.6 million at a weighted average price of $27.51 per share on January 7 and 9, 2026, which represents 71.82% of his direct equity stake [4][5] - Following the transaction, Mr. Gilboa's direct equity stake fell to 37,247 shares, valued at about $1.1 million as of January 9, 2026 [2][5] - The shares were sold at a slight discount to the market price, which was $29.09 as of January 13, 2026 [1] Financial Performance - Warby Parker's third quarter revenue grew 15% year over year to $221.7 million, with a net income of $5.9 million, a significant improvement from a net loss of $4.1 million in the previous year [11] Market Context - The stock reached a 52-week high of $31 on December 11, 2025, following the announcement of AI-powered eyeglasses, indicating strong market interest [8] - The forward price-to-earnings ratio of 62 suggests that the stock may be overvalued, indicating a potential selling opportunity for current shareholders [12] Insider Trading Mechanism - Mr. Gilboa's stock sale was part of a prearranged Rule 10b5-1 trading plan adopted in September 2025, which is commonly used by insiders to avoid accusations of insider trading [9]

J.P. Morgan Healthcare Conference David J. Endicott Chief Executive Officer January 13th, 2026 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," ...

Core Insights - Warby Parker, a direct-to-consumer eyewear company, reported a significant insider sale by co-CEO David Abraham Gilboa, who sold 94,906 shares valued at $2.61 million [1][2][8] Company Overview - Warby Parker generated $850.58 million in revenue over the trailing twelve months (TTM) and reported a net income of $717,000 [4] - The company's stock price increased by 11.77% over the past year, although it lags behind the S&P 500, which rose approximately 18% during the same period [8] Transaction Details - The insider sale involved the conversion and sale of derivative securities under a pre-established Rule 10b5-1 trading plan, indicating planned monetization rather than opportunistic trading [5][8] - Post-transaction, Gilboa retains 37,247 shares, representing 0.03% of the outstanding shares, while still holding significant exposure through derivative securities [5][8] Operational Performance - Warby Parker's third-quarter revenue increased by 15% year-over-year to $221.7 million, with net income rising to $5.9 million from a loss in the previous year [9] - Adjusted EBITDA reached $25.7 million, resulting in a margin of 11.6%, and the number of active customers grew by over 9% on a trailing twelve-month basis [9] Market Position - The company operates a vertically integrated model, controlling costs and delivering value through both physical stores and online platforms, targeting value-conscious consumers in the U.S. and Canada [6][7]